Table 4.

Results from regression models to assess the effect of treatment on selected outcome in the matched population

	DEB- vs Lipiodol-TACE (unadjusted)			DEB- vs lipiodol-TACE (adjusted for PS)
	Coef.	p value	95% CI	Coef.	p value	95% CI
Hospitalization (days)*	−0.624	0.029	(−1.181;−0.066)	−0.624	0.028	(−1.179;−0.068)
Periprocedural complications
No	Reference value
Grade 1	−1.294	0.016	(−2.352;−0.237)	−1.306	0.016	(−2.369;0.242)
Grade 2	−0.302	0.069	(−2.311;0.088)	−1.116	0.069	(−2.316;0.085)
Grade 3	−0.889	0.472	(−3.309;1.531)	−0.881	0.476	(−3.302;1.540)
Grade 4	12.903	0.985	(−1356.99;1382.81)	13.211	0.987	(−1610.7;1637.12)
1-month target tumor response
CR	Reference value			Reference value
PR	−0.009	0.978	(−0.673;0.654)	−0.018	0.958	(−0.694;0.658)
SD	−0.113	0.791	(−0.951;0.724)	−0.118	0.784	(−0.957;0.722)
PD	−0.199	0.656	(−1.073;0.676)	−0.219	0.643	(−1.142;0.705)
1-month overall tumor response
CR	Reference value			Reference value
PR	0.144	0.650	(−0.478;0.767)	0.145	0.650	(−0.482;0.773)
SD	−0.124	0.771	(−0.959;0.711)	−0.124	0.771	(−0.960;0.711)
PD	−0.386	0.679	(−2.216;1.443)	−0.383	0.683	(−2.225;1.458)
Best target tumor response
CR	Reference value			Reference value
PR	0.125	0.699	(−0.51;0.76)	0.131	0.693	(−0.517;0.778)
SD	−0.302	0.544	(−1.278;0.673)	−0.300	0.548	(−1.278;0.678)
PD	0.709	0.567	(−1.717;3.135)	0.715	0.564	(−1.715;3.145)
Death	0.917	0.626	(0.646;1.300)	0.939	0.723	(0.662;1.331)
Target tumor progression	0.717	0.084	(0.492−1.046)	0.749	0.138	(0.512−1.097)
Tumor progression	0.807	0.270	(0.551−1.181)	0.888	0.545	(0.606−1.303)
Extrahepatic progression	0.771	0.369	(0.438;1.359)	0.842	0.553	(0.476;1.488)
Post-TACE liver transplantation	1.832	0.105	(0.882;3.807)	1.895	0.096	(0.894;4.017)

*Values reported are referred to results from simple and multiple linear regression analysis; **Values reported are referred to results from simple and multiple multinomial regression analysis; ***Values reported are referred to results from simple and multiple non-parametric Cox models

PS, propensity score